CoQ10 is concentrated in healthy heart muscle, and CoQ10 deficiency is associated with heart failure.6-7 In one randomized controlled study, patients with moderate-to-severe heart failure who received 100 mg CoQ10 three times daily in addition to standard treatment showed improved symptoms and reduced risk of major cardiovascular events.1
In another trial that assessed circulating levels of CoQ10 in 257 cardiac patients, those with in-hospital mortalities had significantly lower levels of CoQ10.8 In a recent analysis of 14 randomized controlled trials, which included over 2,000 patients with heart failure, supplementation with CoQ10 resulted in a 31% lower mortality rate and an increased exercise capacity as compared with placebo.9
An examination of seven systematic reviews suggests CoQ10 supplementation is beneficial for heart failure patients,10 while another systematic review of 28 trials found CoQ10 enhanced exercise capacity, improved symptoms, and lowered blood pressure levels in heart failure patients.11 Other research indicates heart failure patients with lower CoQ10 levels have up to a two-fold risk of dying as compared to those with higher CoQ10 levels.12
As shown in several studies conducted by Life Extension Scientific Advisory Board Member Peter H. Langsjoen, MD, FACC, CoQ10 supplementation is especially important for individuals on cholesterol-lowering statin therapy (HMG CoA reductase inhibitors). Statin medications block the biosynthesis of both cholesterol and CoQ10, and they worsen heart muscle dysfunction in heart failure patients.16-19 In one study, diastolic dysfunction (heart muscle weakness) occurred in 70% of previously normal patients treated with 20 mg per day of Lipitor for six months. This heart muscle dysfunction was reversible with 100 mg of CoQ10 three times daily.15
Three comprehensive reviews have investigated 19 different clinical trials on the use of CoQ10 in heart failure.13-15 The results of 13 randomized controlled trials, encompassing 395 participants, revealed that CoQ10 supplementation led to a statistically significant average net increase of 3.7% in ejection fraction.
Supplement Facts
Serving Size 1/2 gram
Amount Per Serving
Coenzyme Q-10 (as ubiquinone) 40% CWS 200 mg
Other ingredients: gamma cyclodextrin
Non-GMO
Dosage and Use
- Take 1/2 gram daily, before lunch and dinner, or as recommended by a healthcare practitioner.
Warnings
- KEEP OUT OF REACH OF CHILDREN
- DO NOT EXCEED RECOMMENDED DOSE
- Do not purchase if outer seal is broken or damaged.
- When using nutritional supplements, please consult with your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.
*These statements have not been evaluated by the FDA and are not intended to diagnose, treat, cure or prevent any disease or health condition.
References
- Mortensen SA. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2(6):641-649.
- Langsjoen PH, Langsjoen JO, Langsjoen AM, Lucas LA. Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. BioFactors. 2005;25(1-4):147-152.
- Langsjoen P, Littarru G, Silver M. Potential role of concomitant coenzyme Q~ 1~ 0 with statins for patients with hyperlipidemia. Current Topics in Nutraceutical Research. 2005;3(3):149.
- Folkers K, Langsjoen P, Willis R, Richardson P, Xia LJ, Ye CQ, Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proceedings of the National Academy of Sciences of the United States of America. Nov 1990;87(22):8931-8934.
- Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A. Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction. The American journal of cardiology. Nov 15 2004;94(10):1306-1310.
- Aggarwal M, Bozkurt B, Panjrath G, et al. Lifestyle Modifications for Preventing and Treating Heart Failure. Journal of the American College of Cardiology. 2018;72(19):2391.
- Rosenfeldt, F. L., Haas, S. J., Krum, H. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21(4):297–306.
- Shimizu M. Low circulating coenzyme Q10 during acute phase is associated with inflammation, malnutrition, and in-hospital mortality in patients admitted to the coronary care unit. Heart and vessels. 2017;32(6):668-673.
- Lei L. Efficacy of coenzyme Q10 in patients with cardiac failure: a meta-analysis of clinical trials. BMC cardiovascular disorders. 2017;17(1):196-196.
- Jafari M, Mousavi SM, Asgharzadeh A, Yazdani N. Coenzyme Q10 in the treatment of heart failure: A systematic review of systematic reviews. Indian Heart Journal. 2018;70:S111-S117.
- Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. BioFactors (Oxford, England). 2003;18(1-4):91-100.
- Molyneux SL, Florkowski CM, George PM, Pilbrow AP, Frampton CM, Lever M, Richards AM. Coenzyme Q10: an independent predictor of mortality in chronic heart failure. Journal of the American College of Cardiology. Oct 28 2008;52(18):1435-1441.
- Soja, A. M., and Mortensen, S. A. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol. Aspects Med. 1997;18 Suppl:S159–68.
- Sander, S., Coleman, C. I., Patel, A. A., Kluger, J., and White, C. M. The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J. Card. Fail. 2006;12(6):464–72.
- Fotino, A. D., Thompson-Paul, A. M., and Bazzano, L. A. Effect of coenzyme Q₁₀ supplementation on heart failure: a meta-analysis. American Journal of Clinical Nutrition. 2013;97(2):268–75.
- Foley PM. Clinical Key. First Consult; Heart Failure. Available at: www.clinicalkey.com. Accessed 7/19/2013. 2012.
- Hunt, S. A., Abraham, W. T., Chin, M. H., 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol. 2009;53(15):e1–e90.
- Heidenreich, P. A., Albert, N. M., Allen, L. A., et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association. Circ Heart Fail. 2013; 6(3):606-19.
- Brum PC, Bacurau AV, Medeiros A, Ferreira JC, Vanzelli AS, Negrao CE. Aerobic exercise training in heart failure: impact on sympathetic hyperactivity and cardiac and skeletal muscle function. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas / Sociedade Brasileira de Biofisica … [et al.]. Sep 2011;44(9):827-835.
Coenzyme Q10 is an essential component of healthy mitochondrial function.1-7
CoQ10 is required to convert fats and sugars into cellular energy, yet the natural production of CoQ10 declines with advancing age.8 When the body has an ample amount of CoQ10, the mitochondria can work most efficiently in cells everywhere, including the most densely populated area, the heart.9,10 CoQ10 is also a potent antioxidant, helping protect the proteins, lipids and DNA of mitochondria from oxidation, and supporting mitochondrial function.11
When coenzyme Q10 is orally ingested, only a certain percentage is absorbed into the bloodstream. Higher doses of CoQ10 provide significantly better effects than typical doses. Since CoQ10 is such an expensive nutrient, an alternative to taking higher doses is to increase the amount of CoQ10 that is absorbed.
More References:
- J Am Coll Nutr. 2001 Dec;20(6):591-8.
- Free Radic Res. 2002 Apr;36(4):445-53.
- Int J Biochem Cell Biol. 2005 Jun;37(6):1208-18.
- Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8892-7.
- Neurobiol Dis. 2005 Apr;18(3):618-27.
- J Mol Neurosci. 2006;28(2):125-41.
- Brain Res Bull. 2006 Jun 15;70(1):22-32.
- FEBS Lett. 1999 Jan 25;443(2):163-6.
- Eur Heart J. 2006 Nov;27(22):2675-81.
- Biofactors. 2005;25(1-4):137-45.
- Mol Biotechnol. 2007 Sep;37(1):31-7.
Reviews (0)
There are no reviews yet.